# Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

> **NCT05600114** · PHASE2 · COMPLETED · sponsor: **EmpowerPharm Inc.** · enrollment: 239 (actual)

## Conditions studied

- Social Anxiety Disorder

## Interventions

- **DRUG:** Cannabidiol oral solution
- **DRUG:** Cannabidiol oral solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05600114
- **Lead sponsor:** EmpowerPharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-27
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05600114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05600114, "Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05600114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*